Table 3.
Effects of DHA administration on hepatic and systemic hemodynamics and serum markers in a rat model of advanced chronic liver disease (ACLD).
| Parameter | Vehicle | DHA | p Value |
|---|---|---|---|
| PP (mmHg) | 13.91 ± 0.60 | 12.05 ± 0.57 | 0.03 |
| PBF (mL·min−1) | 15.66 ± 2.54 | 18.21 ± 2.31 | >0.20 |
| IHVR (mmHg·min·mL−1) | 1.05 ± 0.15 | 0.79 ± 0.11 | 0.16 |
| SMABF (mL·min−1) | 8.37 ± 0.91 | 10.03 ± 1.45 | >0.20 |
| MAP (mmHg) | 116.23 ± 5.40 | 99.92 ± 6.25 | 0.1 |
| HR (beats·min−1) | 415 ± 13 | 383 ± 17 | 0.15 |
| AST (U/L) | 155.8 ± 17.08 | 115.8 ± 9.05 | 0.04 |
| Albumin (U/L) | 31.2 ± 0.32 | 30.27 ± 0.53 | >0.20 |
Results are expressed as mean ± S.E.M. n = 11 and n = 14, respectively, for vehicle and DHA. PP, portal pressure; MAP, mean arterial pressure; PBF, portal blood flow; IHVR, intrahepatic vascular resistance; SMABF, superior mesenteric arterial blood flow; HR, heart rate; AST, aspartate aminotransferase.